Compare Vanguard Total International Bond Index Fund ETF (BNDX) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total International Bond Index Fund ETF vs Novartis AG — how do they compare? Vanguard Total International Bond Index Fund ETF trades at $48, while Novartis AG trades at $151.07 (market cap $288.65B). The key difference: Novartis AG pays a 3.15% dividend while Vanguard Total International Bond Index Fund ETF pays none, and Novartis AG is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BNDX | NVS | |
|---|---|---|
52-Week High | $49.91 | $168.62 |
52-Week Low | $47.57 | $113.50 |
Market Cap | — | $288.65B |
Sector | — | Health |
Enterprise Value | — | $328.67B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNDX trades at $47.89, down 0.4% with a bearish technical signal from moving averages. The ETF shows neutral momentum oscillators but faces pressure from rising bond yields and Fed uncertainty. Recent news highlights strong bond ETF inflows as investors seek yield amid market volatility, though inflation concerns persist.
Outlook remains cautious due to potential Fed rate hikes and macroeconomic headwinds. The fund offers steady income through dividends but faces valuation pressure from rising rates. Key risks include interest rate sensitivity and global economic shifts impacting international bond performance.
Novartis (NVS) trades at $153.37, down 0.44% today, with a bullish technical signal from moving averages. The company reported $56.67B revenue in 2025 with strong profitability margins (net income margin 23.92%) and recently expanded its oncology pipeline through acquisitions like Myricx Bio. Earnings have been mixed, with a miss in Q1 2026 but a beat in Q4 2025.
Outlook remains stable with revenue projections near $56.6B for 2026, though debt-to-asset ratio has risen to 30.26%. Risks include pipeline execution and competitive pressures. Analysts show cautious optimism with 68% hold ratings, reflecting balanced growth and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Total International Bond Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.
Read more on BNDX →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
